Physician

Alejandro David Vando Pedrosa, MD

According to 2025 Medicare claims, Alejandro Pedrosa, MD (NPI: 1295212645) practices family practice in the Crestview-Fort Walton Beach-Destin, FL market, with the plurality of this provider's patient population coming from Okaloosa, FL. This provider's primary affiliated billing organization is FLORIDIAN HOSPITALIST SERVICES, LLC (NPI: 1881049997; TIN: 463077526) and primary practice location at 32539-5352.

Pedrosa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 118 traditional Medicare patients, billed 334 HCPCS/CPT codes, and received $26,787 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 3,651 prescription claims across 294 beneficiaries totaling $263,372 in drug costs, led by Eliquis (Apixaban). DME data shows 146 claims. Open Payments data shows 4 records totaling $62. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,235 to $263,372. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	14	37	$1,545
2024	118	334	$26,787

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	14	55	$3,235
2021	59	251	$19,407
2022	112	561	$73,815
2023	279	1,142	$123,992
2024	294	3,651	$263,372

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	146	$14,392

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	35	55	$152
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	18	28	$93
99239	Hospital discharge day management, more than 30 minutes	40	40	$89
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	36	92	$62
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	19	44	$30

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	47	1,610	$33,937
Xarelto	Rivaroxaban	36	1,800	$32,109
Ozempic	Semaglutide	14	658	$16,444
Farxiga	Dapagliflozin Propanediol	28	792	$12,824
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	480	$10,239

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	11	$8,384
J7605	Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms	N	N/R	23	$1,893
E0601	Continuous positive airway pressure (cpap) device	Y	N/R	34	$1,867
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	23	$1,242
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	24	$621

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$62	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alejandro David Vando Pedrosa, MD?

Tedicare shows public-source Medicare data for Alejandro David Vando Pedrosa, MD (NPI 1295212645), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alejandro David Vando Pedrosa, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alejandro David Vando Pedrosa, MD?

Alejandro David Vando Pedrosa, MD is linked to FLORIDIAN HOSPITALIST SERVICES, LLC (billing NPI 1881049997) in the available physician profile data.

Does Alejandro David Vando Pedrosa, MD have Open Payments data?

Alejandro David Vando Pedrosa, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.